QUESTCOR PHARMACEUTICALS INC Balance Sheet

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Balance Sheets

In millions of USD, except per-share amounts

	Q2 FY2014 As of Jun 30, 2014	Q1 FY2014 As of Mar 31, 2014	Q4 FY2013 As of Dec 31, 2013	Q3 FY2013 As of Sep 30, 2013	Q2 FY2013 As of Jun 30, 2013	Q1 FY2013 As of Mar 31, 2013	Q4 FY2012 As of Dec 31, 2012	Q3 FY2012 As of Sep 30, 2012	Q2 FY2012 As of Jun 30, 2012	Q1 FY2012 As of Mar 31, 2012	Q3 FY2011 As of Sep 30, 2011	Q2 FY2011 As of Jun 30, 2011
ASSETS
Cash and cash equivalents
Short-term investments
Total cash, cash equivalents and short-term investments
Accounts receivable, net of allowances for doubtful accounts of $408 and $475 at June 30, 2014 and December 31, 2013, respectively
Inventories, net of allowances of $1,441 and $1,329 at June 30, 2014 and December 31, 2013, respectively
Restricted cash - current portion
Prepaid income taxes
Prepaid expenses and other current assets
Deferred tax assets
Total current assets
Property and equipment, net
Purchased technology, net
Goodwill
In process R&D asset
Intangibles and other non current assets, net
Restricted cash
Deposits and other assets
Total assets
LIABILITIES AND SHAREHOLDERS’ EQUITY
Accounts payable
Accrued compensation
Sales-related reserves
Accrued royalties
Dividend payable
Current portion of contingent consideration associated with the acquisition of BioVectra
Current portion of in process R&D liability
Current portion of non-contingent liability associated with the acquisition of Synacthen and Synacthen Depot
Income taxes payable
Current portion of long-term debt
Other accrued liabilities
Total current liabilities
Long-term debt, less current portion
Contingent consideration associated with acquisition of BioVectra
Non-contingent liability associated with the acquisition of Synacthen and Synacthen Depot
In process R&D liability
Non current deferred tax liability
Other non current liabilities
Total liabilities
Shareholders’ equity:
Preferred stock, no par value, 5,334,285 shares authorized; none outstanding
Common stock, no par value, 105,000,000 shares authorized, 61,448,937 and 60,137,758 shares issued and outstanding at June 30, 2014 and December 31, 2013, respectively
Retained earnings
Accumulated other comprehensive (loss) income
Total shareholders’ equity
Total liabilities and shareholders’ equity

Comments